å»è¬åå ¬è¡šãããæŽå¯
Cytotoxic åžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032ã°ããŒãã«Cytotoxicå»è¬ååžå ŽèŠæš¡ã¯ã2025幎ã«15.4åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«25.7åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®7.3%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«Cytotoxicè¬ã¯ã现èåè£ãšDNAã¬ããªã±ãŒã·ã§ã³ã劚ããããšã«ãã£ãŠãæ¥éã«åè£ããç现èãç Žå£ããããã«èšèšãããååŠçæ³è¬ã§ãã ãããã¯ãã¢ã«ãã«åå€ãæmetabolitesãããã³ãã€ã¯ããã¥ãŒãé»å®³å€ãå«ã¿ãŸãã ããæ²»ç äœå幎ãã®éã æŽå²çã«ãã·ãæ¯æ§ã¯ãæšçããã³å ç«è «çè¬... ãã£ãšèŠã
Pemphigus Vulgaris æ²»çåžå ŽèŠæš¡ãšäºæž¬ â 2025 â 20322025幎ãã2032幎ãŸã§ã®USD 320çŸäžç±³ãã«ã§äŸ¡å€ããããšæšå®ããã2032幎ãŸã§USD 630çŸäžç±³ãã«ã«éãããšäºæ³ããããååç©ã®å¹Žéæé·ç(CAGR)ã10.2%ã«è¡šç€ºããããããã£ãŒã«pemphigus ã® vulgaris ã®ããã®åŠçœ®ãããã¯ãã¯äž»ã«èªåæäœåªä»ãããç®ã®ãŸããé²ãããã«å ç«èª¿ç¯ãç®æšãšããŸãã æŽå²çã«ãã³ã«ãã³ã¹ããã€ããã¢ã¶ããªããªã³ãªã©ã®å ç«æå¶å€ã¯ãã¡ã€ã³ã¹ãã€çæ³ã§ãã£ããã察ççãªææžãæäŸããããé·æçãªå¯äœçšãæã€ã è¿å¹Žããªããã·ããã®ãããªãã€ãªããž... ãã£ãšèŠã
Anticonvulsantå»è¬ååžå Žã¯ãUSD 7,213.9ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Mnã¯USD 8,400.9ã«éãããšäºæ³ããã 2032幎ã2025幎ãã2032幎ã«ãããŠ2.2%ã®ååç©å¹Žéæé·ç(CAGR)ãåºå±æçºäœè¬(æããããè¬)ã¯ãããšããšã¯ãæµè¡ç²Ÿç¥ã§äººã ãæ²»çããããã«èšèšãããŸããã ç¬æã«è³æ©èœé害ãé»å®³ããè³å ã®é»æ°æŽ»åã®çªç¶ã®ç Žè£ã§ããåçºã®çºäœã¯ã粟ç¥ã®äž»èŠå åã§ãã äžéšã®çºäœã¯ãæèãå¥åŠãªæèŠã®åªå€±ãªã©ã®å°é£ãåŒãèµ·ãããŸãããä»ã®äººã¯ã身äœãæºããããã¿ãåŒãèµ·ãããŸãã é²é£è¬(AEDs)ã¯ãäžè¢çãçé çãç¥çµé害ã䞡極é害ãªã©ã®ç ... ãã£ãšèŠã
Organ Transplant Immunosuppressant Drugs Marketã¯ã2025幎ã«USD 5.5 Bnã§è©äŸ¡ããã2032幎ã«USD 6.81 Bnã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®3.1%ã®ååç©ã®å¹Žéæé·ç(CAGR)ã瀺ãã äžççãªèåšç§»æ€å ç«æå¶è¬åžå Žã«é¢ããã¢ããªã¹ãã®æèŠ:èæœåãã人å£ãšèåšé害ã®äžæçã«ãããèåšç§»æ€ã®éèŠã¯äžçäžã§å¢å ããŠããŸãã æåŸã®æ®µéã®èåšé害ãæã€æ£è ã¯ããã°ãã°ä»ã®éžæè¢ã¯ãããŸããããèåšãåãã ãã©ã³ã¹ãã©ã³ã æé ã ãªã«ã¬ã³ç§»æ€å ç«æå¶è¬ã¯ããã®çç±ãèŠæ±ãããŠãããšããããã®éèŠã¯å¹Žã å¢å ã... ãã£ãšèŠã
ããã¥ã©ãŒæµ®è «æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ã®USD 5.9åç±³ãã«ã§åžå ŽèŠæš¡ãè©äŸ¡ããã2032幎ãŸã§ã«USD 10.3åãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®8.2%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«Macular æµ®è «æ²»ç補åã«ã¯ãç³å°¿ç æ§ç¶²èçãç¶²èè»èããŸãã¯è¡åŸã®ççã«é¢é£ããç¶²èè «ã®è «è¹ã管çããããã«èšèšãããå»è¬åãå»çæ©åšã®å€æ§ãªç¯å²ãå«ãŸããŠããŸãã äž»ãªè£œåã«ããŽãªã¯ãæVEGF(è¡ç®¡å èæé·å å)泚å°ãã³ã«ãã³ã¹ããã€ãã€ã³ãã©ã³ããã¬ãŒã¶ãŒå ååºè£ 眮ã§ããranibizumabãaflibercep... ãã£ãšèŠã
æææè¬åžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ãã2032幎ãŸã§ã®USD 105.8åç±³ãã«ã§åžå ŽèŠæš¡ãè©äŸ¡ãããUSD 160.3åç±³ãã«ã«2032åãã«ã«éãããšäºæ³ãããŸãããããã£ãŒã«æææè¬ã¯ãæèãæãŠã€ã«ã¹ãæçèè¬ãããã³ç åäœã«ãã£ãŠåŒãèµ·ããããææçãäºé²ãŸãã¯æ²»çããããã«èšèšãããæéº»è¬ã®åºç¯ãªã¹ãã¯ãã«ãå«ã¿ãŸãã ã³ã¢è£œåã«ããŽãªã¯ãåºã¹ãã¯ãã«æçç©è³ªãã€ã³ãã«ãšã³ã¶ãHIVãããã³èçãã¢ãŸãŒã«ããšããã«ã³ãžã³ãªã©ã®æçèå€ãããã³æãã©ãªã¢ååç©ã§æ§æãããŠããŸãã ããããæèæ§(AMR)ã®äžæã¯ãæ°ããè¬ã®ã¯ã©ã¹ãçµã¿åããçæ³ãããã³æ®ºè... ãã£ãšèŠã
ã·ã¥ã€ãœãã¬ã³ãã£ã¢ æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«ã»ã·ãŸãã¬ã³ãžã¢ æ²»ççšåžå ŽèŠæš¡ã¯ã2025幎ã®USD 7.2åã§è©äŸ¡ããããšæšå®ããã2032幎ã«12.4åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®8.1%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«Schizophreniaã®æ²»çãããã¯ãã¯ç²Ÿç¥ç ã®åŸŽåã管çããå¿è匷ãçµæãæ¹åããããã«èšèšãããŠããæç²Ÿç¥è¬ãé·æéäœçšã®æ³šå°å¯èœãªããã³adjunctiveçæ³ã®ç¯å²ãæž¡ããŸãã ãããã¯ã第äžäžä»£(å žåç)ããã³ç¬¬2äžä»£(å žåçãª)ãªã¹ããªãã³ãaripiprazoleããã... ãã£ãšèŠã
æ¯ç§çšã«ãŒãªãŒãºåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«ãã³ã¿ã«ã±ã€ã³ãºåžå ŽèŠæš¡ã¯ã2025幎ã®USD 8.5åã§è©äŸ¡ããã2032幎ãŸã§ã«USD 12.9åã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®6.3%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«ãã³ã¿ã«ã±ã¢è£œåã«ã¯ãæ¯ã®è æãã³ã³ãããŒã«ããå£è ã®å¥åº·å¹æãæ¹åããããšãç®çãšããäºé²ãå埩ããã³èšºæãœãªã¥ãŒã·ã§ã³ã®åºãç¯å²ãå«ãŸããŠããŸãã ãããã®è£œåã¯ãããåç©ããŒã¹ã®æ¯ç£šãç²ãã¯ãã¹ã壿Žãã现èã®é žæ»æãããšãã¡ã«ãä¿è·ããæ¯ç§çšã·ãŒã©ã³ããåå°ããŠããŸãã 修埩æ¯ç§å»ãåææš¹èãã¬ã©ã¹ã€ãª... ãã£ãšèŠã
ç¬é¢ç¯ç åžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032ã°ããŒãã«ã«ã€ã³é¢ç¯ç åžå ŽèŠæš¡ã¯ã2025幎ã«1,45åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«2,85åç±³ãã«ã«éããèŠèŸŒã¿ã§ã2025幎ãã2032幎ãŸã§ã®10.1%ã®ååç©å¹Žéæé·ç(CAGR)ãå ããŠããŸãããããã£ãŒã«ç¬ã®é¢ç¯ç補åã«ã¯ãç¬ã®çã¿ãççãããã³é¢ç¯å€æ§ã管çããããã«èšèšãããå»è¬å補å€ãæ é€è£å©é£åãããã³çæ åŠãå«ãŸããŸãã äžè¬çãªè£œåã«ããŽãªã¯ãéã¹ããã€ãæççè¬(NSAID)ãç æ°ä¿®é£Ÿéªšé¢ç¯çè¬(DMOAD)ãã°ã«ã³ãµãã³ããã³ã³ã³ããã€ãã³ãµããªã¡ã³ããããã³å¹¹çްèçæ³ã§æ§æãããŠããŸãã ãããã®è£œåã¿ãŒ... ãã£ãšèŠã
éã¢ã«ã³ãŒã«æ§Seatohepatitis(NASH)æ²»çè¬ããã³èšºæåžå Žã¯USD 25,331.1ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Mnã¯USD 91,456.5ã«éãããšäºæ³ãããŸã 2032幎ã2025幎ãã2032幎ã«ãããŠ20.13%ã®ååç©å¹Žéæé·ç(CAGR)ãåºå± äžççãªéã¢ã«ã³ãŒã«æ§èè±ç(NASH)æ²»çè¬ããã³èšºæåžå Žã¯ãNASHã®åœ±é¿ãåãã人å£ã®å¢å ã«ãã匷åãªæé·ãçµéšããäžçäžã§ç³å°¿ç ããã³è¥æºã®äººå£ã®å¢å ã«äžæããŠããŸãã ãŸããæ¿åº/éæ¿åºæ©é¢ã«ããå®å šãã€å¹æçãªNASHæ²»çè¬ããã³èšºæããã³ã€ãã·ã¢ããã«å¯ŸããéèŠã®å¢å ã¯ãåžå Žã®æé·ãåŸæŒãããããšã... ãã£ãšèŠã
äºé²æ¥çš® 人éã¯ã¯ãã³ åžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032ã°ããŒãã«äºé²äººéã¯ã¯ãã³ åžå ŽèŠæš¡ã¯ã2025幎ã«72.8åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«115.3åç±³ãã«ã«éããèŠèŸŒã¿ã§ã2025幎ãã2032幎ãŸã§ã®6.8%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«äºé²çãªäººéã®ã¯ã¯ãã³ã¯ãç åäœãžã®æé²åã«æææ§çŸæ£ãé²ãå ç«åå¿ãåºæ¿ããããã«èšèšãããçç©åŠç補å€ã§ãã ãããã®è£œåã¯ããŠã€ã«ã¹ã现èã®æåæåãå ç«ã·ã¹ãã ã«å°å ¥ãããéæŽ»æ§åãæžè¡°ããµããŠããããã³ã³ãžã¥ã²ãŒãããŸãã¯mRNAããŒã¹ã®è£œå€ã§æ§æãããŠããŸãã é·å¹Žã«ããããã¯ã¯ãã³éçºã¯åŸ... ãã£ãšèŠã
Epidermolysis ãã«ãªãŒãµ åžå Žã¯ç±³ãã«4,715.0ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Mnã¯USD 9,913.2ã«éãããšäºæ³ããã 2032幎ã2025幎ãã2032幎ã«ãããŠ11.2%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºã ãšãããŒã¢ã·ã¹ãã«ãªãŒãµã¯ãç®èãéåžžã«è匱ã«ãªãåå ã®ãŸããªç¶æ¿ãããç®èé害ã®ã°ã«ãŒãã§ãã ç®èãžã®ãã©ãŠããæ©æŠã¯çã¿ã䌎ããŸããåŒãèµ·ããå¯èœæ§ããããŸãã 衚ç®åè§£ã®ãã«ãªãŒãµã®åŸŽåã¯å®¹æã«ãè¶³ã®æãããŠãœãŒã«ã®ãŸããå·ã€ããããŸãã¯æéäžã®è²ãå€ãããããããªãåããããç®ããã³ç®ããã³éã®åããªãç®ãå«ãç®ããŸããŸããå«ãŸããŠãã3ã€... ãã£ãšèŠã
ã¢ã«ã¯éœæ§èºããæ²»çåžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032äžççãªã¢ã«ã¯éœæ§èºããæ²»çåžå ŽèŠæš¡ã¯ã2025幎ãã2032幎ãŸã§ã®USD 4.7åã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã®USD 9.8åã«éãããšäºæ³ãããååç©ã®å¹Žéæé·ç(CAGR)ã2025幎ãã2032幎ãŸã§11.2%ã«æ¡å€§ããããããã£ãŒã«ALKéœæ§èºããã®æ²»çã¯ãéå°çްèèºãã(NSCLC)ã®ãµãã»ããã§çºèŠãããç°åžžãªanaplasticãªã³ãè «ãããŒãŒ(ALK)éºäŒåèåæŽ»æ§ãé»å®³ããæšççæ³ã§æ§æãããŠããŸãã ãããã®æ²»çã¯ãäž»ã«ALKã·ã°ãã«äŒéçµè·¯ããããã¯ããå°ååããã·ã³ãããŒãŒé»å®³å€(TKI)ãå«... ãã£ãšèŠã
H1N1ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã¯ãäž»ã«åŒåžåšç³»ã«åœ±é¿ãåãŒãã¹ã€ã³ãã«ãšã³ã¶ãšããŠäžè¬çã«ç¥ãããŠãããŠã€ã«ã¹æ§çŸæ£ãåŒãèµ·ãããŸãã Swine 㯠H1N1 ç·åŒµããã®äŒæã«ãã£ãŠç¹åŸŽä»ããããŸãã H1N1ãã©ã ã®çç¶ã¯ãç±ãå³ãåã®çã¿ã錻氎ãèµ€ã®ç®ãäœçãé çãç²åŽãäžç¢ã§ãã H1N1ã¯ãæ±æããã空æ°ãŸãã¯å°ççãªå ŽæãšãŠã€ã«ã¹ã«ææããæ¥è§Šãä»ããŠåºãããŸãã H1N1ææã¯ãæ°ç®¡æ¯çãèºçãªã©ã®ä»ã®æ ¢æ§åŒåžåšçŸæ£ãæªåãããå¯èœæ§ããããŸãã ãããã¯ã¹ããããŠæã«ã¯åŒåžåšé害ã«ããæ»ã§ãããH1N1ã¯ã¯ãã³ã¯2009幎以æ¥ãH1N1ãã³ãããã¯ã«åãçµãéèŠãªé©æ°ã§ãã åœ... ãã£ãšèŠã
ã³ãã³ããã³Rectalçã¯åžå ŽèŠæš¡ãšäºæž¬ããã©ãã° - 2025 - 20322025幎ïœ2032幎ã«ãããŠãäžçå€§è žããå»è¬ååžå ŽèŠæš¡ã¯ã8.3%ã®ååç©å¹Žéæé·ç(CAGR)ã2025ãã2032幎ãŸã§ã«14.6åç±³ãã«ã«éããèŠèŸŒã¿ã§ããããããã£ãŒã«ã³ãã³ããã³ãªã¯ã¿ã«çè¬ã¯è «çã®æé·ãæå¶ãã転移ãé²ããå¿è匷ãçåãæ¹åããããã«èšèšãããŠããæ²»çè¬ã®åºãç¯å²ãå«ãã§ããŸãã ãããã®è£œåã¯ãEGFRãŸãã¯VEGFä¿¡å·çµè·¯ããããã¯ããæšççæ³ãããã³ç现èã«å¯Ÿããäœã®å ç«ç³»ã掻æ§åããæ¬¡äžä»£å ç«çæ³ãªã©ã®ååŠçæ³è¬ã䌎ããŸãã çµå£ããã³éèå 補å€ã¯ãæè¬ã®æè»æ§ãæäŸããªãã... ãã£ãšèŠã
ã¢ã³ãããã³ãã³åžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032äžçã¢ã³ãããã³ãã³åžå ŽèŠæš¡ã¯ã2025幎ãã2032幎ãŸã§ã®USD 1.65åç±³ãã«ã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã®USD 2.78åãã«ã«éãããšäºæ³ãããããããã£ãŒã«ã¢ã³ãããã³ãã³åžå Žã¯è¡ååºã調ç¯ããã®ã«äœ¿çšãããè¡æŒ¿ãŸãã¯çµæãã®æºããåŸãããæ²»çããã³èšºæãããã¯ãã䌎ããŸãã Antithrombinã®æ¿çž®ç©ã¯å 倩æ§ãŸãã¯åŸãããæ¬ é¥ã®æ£è ã«ãæ·±ãéèã®è¡æ çãèºå¡æ çã®ãããªæ¡ä»¶ãé²ãããããŠè¡ç®¡ã®ååºãæãªãããã«ç®¡çãããŸãã åçµä¹Ÿç¥ãããç²ããã³æ³šå°å¯èœãªå ¬åŒã¯ã人éã®è¡æŒ¿ç±æ¥ããã³çµæãã®å€åœ¢ã§å©çš... ãã£ãšèŠã
æ§çã«ééæ§çŸæ£(STD)æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«æ§ææç(STD) æ²»çåžå ŽèŠæš¡ã¯ã2025幎ã«15.7åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«25.4åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®7.3%ã®ååç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«STDã®åŠçœ®ã®åžå Žã¯ã®ãããªäŒæã管çããããšãç®çãšããè¬å€ããã³çç©çãããã¯ãã®åºãã¹ãã¯ãã«ããæã£ãŠããŸã ãã€ããæ¢ æ¯ãæ·ç ãã¯ã©ããžã¢ããã«ãã¹ãHPVã æ²»çã«ã¯ãæçç©è³ªãæãŠã€ã«ã¹ãã¯ã¯ãã³ãããã³å±æè£œå€ãå«ãŸããŸãã 補åã®æ¯èгã¯ãæ°ããæçç©è³ªãé·æéäœçšã®æ³šå°åš... ãã£ãšèŠã
é«ãªã³ã³ããã㢠å»è¬ååžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032äžççãªHyperphosphatemia å»è¬ååžå ŽèŠæš¡ã¯ã2025幎ïœ2032幎ãŸã§ã®9.2%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããUSD 6.7åç±³ãã«ã«éããèŠèŸŒã¿ã§ãããããã£ãŒã«Hyperphosphatemiaã®è¬å€ã¯ç³å°¿ç ãçµãæ ¢æ§ã®è èç (CKD)ã®æ£è ã§äž»ã«é«ããããé£é žå¡©ã®ã¬ãã«ãæžããã®ã«äœ¿çšãããæ²»çè¬ã§ãã ã«ã«ã·ãŠã ç³»ãéã«ã«ã·ãŠã ç³»(ã»ãã©ãŒãã©ã³ã¿ã³ã«ãŒãããŒã)ãé系補å€ãªã©ã®ãªã³é žãã€ã³ãã©ãŒã§æ§æãããŠããŸãã ãããã®è£œåã¯ãèè žç®¡ã®é£å¡©ãçµåããããšã«ãããè¡æµãžã®åžåãé²ããŸãã ... ãã£ãšèŠã